October 16, 2024 – Page 8

Ladybug Reports Rapid Growth as Sales Continue to Accelerate Across All Business Segments

Written by Customer Service on October 16, 2024. Posted in Public Companies.

TULSA, Okla., Oct. 16, 2024 (GLOBE NEWSWIRE) — Ladybug Resource Group, Inc.; (OTC PINK: LBRG), now operating as Ladybug Nutratech, a leading player in the health and wellness products sector, continues with sales growth in all business segments of the Company. This trend comes just after the Company’s recent announcement of surpassing $6.0 million USD in revenue for the first half of 2024, a testament to Ladybug’s ongoing strategic efforts in both technological innovation and market expansion. Highlighting year-to-date, Ladybug’s performance has demonstrated impressive revenue growth in the first half of 2024. Various strategic initiatives, including introducing new product lines, strategic acquisitions, and the eCommerce NutraBuddy’s AI-powered platform, targeted to attract over 10 million users in its first-year post-launch,...

Prime Drink Group Raises an Additional $2.2 Million and Provides an Update on the Triani Acquisition

Written by Customer Service on October 16, 2024. Posted in Mergers And Acquisitions.

MONTREAL, Oct. 16, 2024 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has raised an additional aggregate total of approximately $2,200,000 through: the closing of the third and final tranche of its previously announced non-brokered private placement financing of subscription receipts (the “Subscription Receipt Offering”) for gross proceeds of $1,193,500, and the closing of a non-brokered private placement of Units (as defined herein) (the “Unit Offering”) for gross proceeds of $1,000,000. The Subscription Receipt Offering is being completed in connection with the previously announced transaction (the “Transaction”), whereby the Company will acquire all of the issued and outstanding shares (the “Triani Shares”) of Triani Canada Inc. (“Triani”) pursuant to an amended...

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Written by Customer Service on October 16, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived...

Global 3D Printing Medical Devices Market to Evolve at a Phenomenal 17.1% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on October 16, 2024. Posted in Mergers And Acquisitions.

Discover the booming 3D Printing Medical Devices Market, projected to soar from USD 3.28 billion in 2023 to an impressive USD 11.59 billion by 2031, fueled by innovative technologies like Laser Beam Melting and Photopolymerization. Explore unprecedented growth opportunities at a remarkable CAGR of 17.1% and revolutionize healthcare with cutting-edge solutions! Westford, USA, Oct. 16, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the 3D Printing Medical Devices market will attain a value of USD 11.59 billion by 2031, with a CAGR of 17.1% over the forecast period (2024-2031). Surging demand for medical devices around the world and advancements in 3D printing technologies primarily govern 3D printing medical devices market growth potential. Growing use of additive manufacturing practices in the manufacturing industry and rising demand...

Enthusiast’s Luminosity Hosts Invitational Smash Bros Event for over 400,000 Unique Online Viewers

Written by Customer Service on October 16, 2024. Posted in Public Companies.

Luminosity Invitational #2 reached over 400,000 unique online viewers, 58,000 concurrent live viewers, and 600,000 hours watched LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced that its recent Luminosity Invitational: Back 2 School, Luminosity’s second invitational Super Smash Bros Ultimate event of the year, was estimated to reach over 400,000 unique online viewers and peaked at over 58,000 live concurrent viewers during the Grand Finals. The three-day event was held in Miami, Florida, where 16 of the best Super Smash Bros Ultimate players in the world convened to compete for the $10,000 prize pool, generating over 600,000 hours watched. The event’s live concurrent viewership puts it on par with...

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Written by Customer Service on October 16, 2024. Posted in Public Companies.

WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024. The conference is being held in Los Angeles, October 16-19, 2024. Invivyd will be presenting the following oral and poster presentations: Title Presenting Author Presentation Timing Oral Presentation: Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart Anna Holmes, Ph.D., Principal Clinical Scientist October 17 (11:18-11:30am PT/2:18 -2:30pm ET) Poster: Results from a Phase 1 First in Human Study of Pemivibart: An Extended Half-Life Monoclonal Antibody (mAb) Amanda Copans, PharmD, Vice President,...

Emerita Intersects 6.5m of Massive Sulfide Grading 1.1% Copper, 1.1% Lead, 3.1% Zinc, 73.35 g/t Silver And 1.36 g/t Gold at El Cura Deposit, Demonstrating Continuity of Mineralization Along Strike

Written by Customer Service on October 16, 2024. Posted in Public Companies.

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) has intersected significant mineralization in the ongoing drilling campaign at El Cura Deposit, part of Emerita’s wholly owned Iberian Belt West project (“IBW” or the “Project”; Figure 1). IBW hosts three previously identified Volcanogenic Massive Sulfide (VMS) deposits: La Romanera, El Cura and La Infanta. Results contained in this news release are from El Cura deposit area only. Drillhole EC020 intersected 6.5 m grading 1.1% copper, 1.1% lead, 3.1% zinc, 73.35 g/t silver and 1.36 g/t gold. Drillhole EC018 intersected 4.1 m grading 0.3% copper, 0.4% lead, 0.6% zinc, 14.98 g/t silver and 0.36 g/t gold. Drillhole EC019 intersected 0.5 m grading 0.8% copper, 0.3% lead, 1.2% zinc, 21.00 g/t silver and...

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Written by Customer Service on October 16, 2024. Posted in Public Companies.

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases. Title:...

Lifeist Announces Conclusion of Consulting Agreement with Singular Narrative Management Ltd.

Written by Customer Service on October 16, 2024. Posted in Public Companies.

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to support wellness in innovative ways, today announced the termination of its consulting agreement with Singular Narrative Management Ltd. (“Singular”) effective October 31, 2024. Singular will continue to provide its services under the consulting agreement until such time. The parties mutually agreed to terminate the agreement, originally announced on June 30, 2023, and renewed effective August 1, 2024 as Singular’s mandate under the agreement will be completed by October 31, 2024. The agreement with Singular has provided strategic business consulting, product development, and brand marketing services...

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Written by Customer Service on October 16, 2024. Posted in Public Companies.

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05% (APP13007) that led to its approval by the U.S. Food and Drug Administration as a treatment for inflammation and pain following ocular surgery. Eyenovia announced the U.S. launch and commercial availability of clobetasol on September 26, 2024. “We are very pleased...

Day: October 16, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice